EFFICIENCY OF SILDANEFIL MONOTHERAPY IN BENIGN PROSTATIC HYPERPLASIA

0Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

INTRODUCTION: High incidences of benign prostatic hyperplasia and lower urinary tract symptoms have a high socioeconomic importance. There are several published studies which have proved the efficiency of phosphodiesterase type 5 inhibitors in treatment of benign prostatic hyperplasia and lower urinary tract symptoms. However, more studies are needed to make this therapy the standard option for treating benign prostatic hyperplasia and lower urinary tract symptoms. This study was aimed at exploring changes in International Prostate Symptom Score, post voiding residuum and maximal urine flow in benign prostatic hyperplasia and lower urinary tract symptoms patients treated by sildenafil for benign prostatic hyperplasia and lower urinary tract symptoms. Matcrial and Methods. This study, which was conducted as a prospective:controlled, opened, randomized study, included 30 patients with benign prostatic hyperplasia and lower urinary tract symptoms. Research was conducted at the Department of Urology, Clinical Center of Vojvodina (November 2011 till November 2012). The inclusion criteria were as following: >45 years of age, International Prostate Symptom Score >3, prostatic specific antigen

Cite

CITATION STYLE

APA

Grbic, D., Vojinov, S., Jeremic, D., Levakov, I., Dozic, S., & Sekulic, V. (2016). EFFICIENCY OF SILDANEFIL MONOTHERAPY IN BENIGN PROSTATIC HYPERPLASIA. Medicinski Pregled, 69(11–12), 379–383. https://doi.org/10.2298/mpns1612379g

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free